Please login to the form below

Not currently logged in
Email:
Password:

Sanofi wins Eloxatin patent case

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin until August 2012 following a patent challenge from Sun Pharmaceuticals

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin (oxaliplatin) until August 2012 following a patent challenge from Sun Pharmaceuticals.

Sun Pharma was appealing a district court ruling from April 2010 requiring Sun to cease selling its generic oxaliplatin products as of June 30, 2010.

Sanofi had previously reached settlement agreements with several other pharmaceutical companies, including Teva Pharmaceutical and Sandoz, prohibiting the sale of generic Eloxatin products in the US until August, 2012.

In recently released financial results, Sanofi reported the drug had sales €436m for Sanofi during the first half of 2011.

The company said it still sees Eloxatin as an important therapeutic option for healthcare professionals treating patients with colorectal cancer.

19th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics